In a field where hyaluronic acids are often considered to be the same, GenVisc 850 is different because it has a unique reimbursement code and gives you the
regimen options for you to decide what’s best for each individual patient. It’s you after all, that makes
GenVisc 850 work.
Reimbursement Code J7320
Approved for 5 injections, but some patients may benefit from as few as 3 injections.
GenVisc 850 has the largest and longest duration double blind
clinical study of hyaluronic acids for knee osteoarthritis.1
GenVisc 850 has been published in over 30 clinical studies.2
Safe as saline placebo
Free of avian proteins
Demonstrated safe for repeat injection cycles
Provides significant pain relief with results that last 2
Demonstrated improvement in pain relief up to 30 weeks post first injection cycle 2
Demonstrated improvement of total WOMAC index at 30 weeks:
Pain, stiffness and functional capacity 1
Now approved in 64 countries with over 45 million syringes distributed worldwide.2 †